Mike Thompson, MD, PhD, FASCO

VP Hematology (TIME) @TempusAI #PrecisionMedicine #mmsm #lymsm #MDSsm #leusm #CCC19 @COVID19nCCC @ASCO COI:

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Whole-genome sequencing (WGS) identifies clinically relevant alterations in Myelodysplastic Syndromes (MDS) lacking detectable mutations by standard-of-care testing [Sun, Dec 13, 2026] @AlexBataller et al @garciamanero #ASH26 Abs 3835
https://t.co/wJrZgX6D2H #MDSsm #leusm #genome

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Global rates of influenza (FV) and pneumococcal (PV) vaccination in multiple myeloma (MM) patients (Pts) in INSIGHT MM: Impact on healthcare resource utilization (HRU) and overall survival (OS) [6/12/20] @mtmdphd et al. Abst EP967 #EHA25 https://t.co/6CRlZ5sADM #mmsm #IDonc #caxtx #globonc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#EAonc EAA242 - Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) vs Carfilzomib/Pomalidomide/Dex (KPd) in Early Relapse of Multiple Myeloma [Jul 16, 2026 activation] @JanakiramMurali @AjayNookaMD @natashaedwin https://t.co/OnKQTq3b9H #NCT0746380 #mmsm @eaonc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @NatalieCal51870 https://t.co/HIvPd8GEQo
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

PrE1005 - Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone [Bel-VRd vs DVRd) for Newly Diagnosed Multiple Myeloma [NDMM] PI = @myelomaMD https://t.co/3gVVbMpOj2 #NCT07285239 #mmsm @eaonc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma - ENDURANCE [Jul 15, 2026] @myelomaMD et al. @VincentRK @NEJM
https://t.co/VY6hBe0vkh #NCT01863550 #mmsm @eaonc E1A11

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous
https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [v.01/29/26 Add 4] PI= @myelomaMD https://t.co/l71rDRw2Jj #NCT04566328 #mmMRD #mmsm @eaonc @VincentRK @LynneWagnerPhD @mtmdphd

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCJRK #mmsm #bmtsm

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Feasibility of clinical grade whole-genome sequencing [WGS] for comprehensive risk stratification and therapeutic target profiling in multiple myeloma [Sun, Dec 13, 2026] Kesaraju et al. #ASH26 Abs 4066
https://t.co/gbNAHOvfEx #mmsm #cagenome #PrecisionMedicine @washumedicine

[ASH @ASH_hematology]

ASH CRTI offers hematology fellows & junior faculty a year-long experience spanning research methods, statistical analysis, collaboration, & career development. Start your application today!

LOIs are due by Dec. 17: https://t.co/aiilrVEel1

#ASHTrainee

[Ashwin Kishtagari, MD @AshKishtagari]

Going to #ASH26, and the news I'm happiest about isn't mine.

Three IM residents I mentor, Akshay Aluri, Michael Zargari and Pranay Shettywarangale, each won an ASH Abstract Achievement Award! So proud! 🧵1/4
@VUMCDiscoveries @jordanberlin5

[Aakash Desai @ADesaiMD]

MTAP IHC (@CCR_AACR): 243 NSCLCs, 72% driver+
➡️ MTAP loss 17%; early 13%, metastatic 20%
➡️ Stage 4: driver+ 24% vs driver- 14% (p=0.314)
➡️ PRMT5i + TKI > PRMT5i alone in MTAP-del lines
PRMT5i + TKI trials next?
https://t.co/CdP9tGpiaq

@LungCancerRx @OncoAlert @oncodaily

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Sustained disease remission with reduced-intensity allogeneic hematopoietic cell transplant for VEXAS syndrome [Nov 10, 2026] Patel et al. @emmamgroarke @Hemasphere_EHA https://t.co/Qap0HZvDC9 #bmtsm #AMLsm #leusm

[Tempus @TempusAI]

Lung cancer demands clarity at every stage—because every patient’s journey is unique.

This #LungCancerAwarenessMonth, we honor the resilience of the lung cancer community. Tempus is proud to support patients and their care teams with comprehensive genomic profiling, guiding personalized treatment decisions from initial diagnosis to long-term monitoring.

Learn more about our comprehensive portfolio for lung cancer patients: https://t.co/dKqFgBvI7J

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#CardioOnc #amyloidosis

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Patients w/ #amyloidosis & implanted cardioverter defibrillators (mean follow-up of 4.9 yrs) have high rates of mortality w/ similar outcomes for AL & ATTR, and also high rates of inappropriate shocks for both AL and TTR: https://t.co/Zvbs8oOeMr. #alsm

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Enhanced bone marrow Tryptophan–Kynurenine metabolism differentiates monoclonal gammopathy of undetermined significance [MGUS] from multiple myeloma [Sun, Dec 13, 2026] Chawla et al. @MayoCancerCare #ASH26 Abs 3924 https://t.co/Ug0Ag3Bh2w #mmsm #ImmunoOnc #IDonc #caxtx

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

#IDonc #mmsm #ImmunoOnc

[Luciano J Costa @End_myeloma]

Prevent infections with BCMA-directed bispecifics. Simple:
Think BALI #mmsm @MyelomaTeacher

B- actrim M, W, F
A- cyclovir 4ever
L- evofloxacin on month 1
I- VIg moonthly from C2D1

Data in the link

https://t.co/tLJOQgaCV0

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology [Apr 2026] @MellinghoffSC et al. on behalf of the German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO)
https://t.co/G5LZr6CSvC #IDonc #hemeonc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Cancer #ClinicalTrials Eligibility & Therapy Modifications for Individuals w/ Duffy Null–Associated Neutrophil Count [DANC] [Sep 11, 2024] Hibbs et al. @JAMANetworkOpen
https://t.co/TSKz5zSkKL
@ASHClinicalNews Commentary: https://t.co/PiRKAorrxH #mmsm

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

MT @MyelomaTeacher Lauren Merz, MD @LaurenMerzMD explains how a genetic variant called the Duffy antigen, which is more common in people of African or Arabian ancestry, may influence treatment outcomes in multiple #myeloma #mmsm #ASH25
https://t.co/HLoxuSJ8kJ #bmtsm #CancerDisparities #globonc